T3D Therapeutics Overview
- Founded
- 2013
- Status
- Private
- Employees
- 6
- Latest Deal Type
- Grant
- Latest Deal Amount
- $5M
- Investors
- 1
T3D Therapeutics General Information
Description
Developer of a novel drug therapy designed to stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, enabling Alzheimer patients to have a drug that can potentially improve multiple defects and improve memory, motor function and cognition.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare
Primary Office
- 68 T.W. Alexander Drive
- Post Office Box 13628
- Research Triangle Park, NC 27709
- United States
+1 (919) 000-0000
T3D Therapeutics Timeline
T3D Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Grant | 01-Aug-2020 | $5M | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 9. Later Stage VC (Series B) | 04-Nov-2019 | 0000 | 000.00 | Completed | Generating Revenue | |
| 8. Grant | 20-May-2019 | 000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 7. Early Stage VC (Series B) | 10-Mar-2018 | 000 | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 6. Early Stage VC (Series A3) | 11-Mar-2016 | 00.000 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
| 5. Grant | 24-Mar-2015 | 00.000 | 00.00 | Completed | Clinical Trials - Phase 2 | |
| 4. Debt - General | 31-Jul-2014 | 00000 | 00.00 | Completed | Startup | |
| 3. Early Stage VC (Series A2) | 14-Mar-2014 | 00000 | 00.000 | 00.000 | Completed | Startup |
| 2. Debt - General | 24-Jun-2013 | $50K | $487K | Completed | Startup | |
| 1. Angel (individual) | 20-Jun-2013 | $437K | $437K | 00.000 | Completed | Startup |
T3D Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
| Series A2 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A1 | 404,628 | $0.001000 | 6% | $1.08 | $1.08 | 1x | $1.08 | 7.26% |
T3D Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel drug therapy designed to stop or reverse the course of Alzheimer's disease. The company's drug is a
Drug Discovery
Research Triangle Park, NC
6
As of 2020
000.00
000
0000-00-00
0000000000
000.00
000 0000
aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea co
0000 000000000
Boston, MA
0
As of 0000
000.00
0000000000 0
000.00
00000000
ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in re
0000 000000000
Pittsburgh, PA
00
As of 0000
000.00
0000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialT3D Therapeutics Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| EIP Pharma | Venture Capital-Backed | Boston, MA | 0 | 000.00 | 0000000000 0 | 000.00 |
| 000000000 00000000 | Venture Capital-Backed | Pittsburgh, PA | 00 | 000.00 | 0000000000 | 000.00 |
| 0000 | Venture Capital-Backed | San Diego, CA | 00 | 00.000 | 0000000000 0 | |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 0000 | 0000000000 | 0000 |
| 000000 | Formerly VC-backed | Mountain View, CA | 00 | 00000 | 000000&0 | 00000 |
T3D Therapeutics Executive Team (3)
T3D Therapeutics Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barry Buzogany JD | T3D Therapeutics | Board Member | 000 0000 |
| Charles Lineberry Ph.D | T3D Therapeutics | Board Member | 000 0000 |
| John Didsbury Ph.D | T3D Therapeutics | Founder, Chairman of the Board, President & Chief Executive Officer | 000 0000 |
| John Golden | Self | Board Member | 000 0000 |
| Thomas Mendell | Self | Board Member | 000 0000 |
T3D Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialT3D Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Institute On Aging | Government | Minority | 000 0000 | 000000 0 |